Revenue: As of FY2026 Q1, the actual value is USD 22 K, beating the estimate of USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.69.EBIT: As of FY2026 Q1, the actual value is USD -1.93 M.<h4>Segment Revenue</h4><ul><li>Clinical treatment programs – US Revenue for AIM ImmunoTech Inc. was $22 thousand for the three months ended March 31, 2026, marking a 37.5% increase from $16 thousand for the same period in 2025.</li><li>Total Revenues were $22 thousand for the three months ended March 31, 2026, up from $16 thousand for the three months ended March 31, 2025.</li></ul><h4>Operational Metrics</h4><ul><li>Net Loss for the three months ended March 31, 2026, was - $3,023 thousand, an 18.4% decrease compared to a net loss of - $3,705 thousand for the same period in 2025.</li><li>Operating Loss was - $2,226 thousand for the three months ended March 31, 2026, representing a 38.5% decrease from - $3,619 thousand in the prior year period.</li><li>Total Costs and Expenses decreased by 38.2% to $2,248 thousand for the three months ended March 31, 2026, from $3,635 thousand in the comparable period of 2025.<ul><li>Production costs decreased by 60.0% to $4 thousand in 2026 from $10 thousand in 2025.</li><li>Research and development (R&amp;D) decreased by 55.4% to $482 thousand in 2026 from $1,080 thousand in 2025, primarily due to reduced patient enrollment in pancreatic cancer trials and a decision to reduce annual maintenance fees and development of patents not meeting current core objectives, which resulted in a $335 thousand charge to clinical expenses in Q1 2025.</li><li>General and administrative expenses decreased by 30.8% to $1,762 thousand in 2026 from $2,545 thousand in 2025, mainly due to reduced legal fees.</li></ul></li><li>Interest Expense and Other Finance Costs increased by 145.2% to - $304 thousand in 2026 from - $124 thousand in 2025, driven by additional debt from a Note Purchase Agreement entered into on November 18, 2025.</li><li>A Loss on change in fair value of warrant liability of - $468 thousand was recognized in 2026, compared to $0 in 2025, due to the reclassification of Class E &amp; F warrants from liability to equity.</li><li>A Loss on issuance of warrants of - $32 thousand was recognized in 2026, compared to $0 in 2025, related to the Rights Offering.</li></ul><h4>Cash Flow</h4><ul><li>Net cash used in operating activities increased to - $2,719 thousand for the three months ended March 31, 2026, from - $2,361 thousand for the same period in 2025, primarily due to the utilization of cash for accounts payable.</li><li>Net cash (used in) provided by investing activities shifted from $898 thousand provided in 2025 to - $37 thousand used in 2026, largely because the company utilized financing activities instead of investments for operating funds.</li><li>Net cash provided by financing activities significantly increased by 746.5% to $5,587 thousand in 2026 from $660 thousand in 2025, driven by proceeds from a rights offering ($1.8 million), ATM offering ($2.0 million), and warrant exercises ($2.2 million).</li><li>Cash and cash equivalents increased by $2,831 thousand to $5,816 thousand at March 31, 2026, from $2,985 thousand at December 31, 2025.</li></ul><h4>Unique Metrics</h4><ul><li>As of March 31, 2026, AIM ImmunoTech Inc.’s stockholders’ equity was $2.1 million, an improvement from a deficit of - $9,783 thousand at December 31, 2025.</li><li>The company’s stockholders’ equity of $2.1 million as of March 31, 2026, remains below the NYSE American’s minimum requirement of $6 million, leading to substantial doubt about its ability to continue as a going concern.</li><li>The reclassification of Class E &amp; F Common Stock Purchase Warrants from liability to equity resulted in an $8.7 million increase in stockholders’ equity as of March 31, 2026.</li></ul><h4>Future Outlook and Strategy</h4>AIM ImmunoTech Inc. is focusing its efforts on developing Ampligen for late-stage pancreatic cancer, aiming for a Phase 3 study following positive Phase 2 clinical trial data and an agreement with Thermo Fisher Scientific. The company plans to raise capital through equity issuance and warrant exercises to meet NYSE American listing requirements and fund ongoing operations and clinical development, including the DURIPANC study. While the company has a history of successful financing, there is no assurance of future funding, and it may seek additional capital through public/private equity, debt, or collaborative arrangements, which could result in significant dilution.

AIM ImmunoTech | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 22 K